
Opinion|Videos|January 17, 2025
Integrating Emerging BTKi Therapies Into Current Treatment Guidelines
Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell lymphoma (MCL) are addressing unmet needs by providing novel therapeutic options, and explore how the integration of these therapies into current chronic lymphocytic leukemia (CLL) and MCL treatment guidelines could reshape management strategies, with consideration given to factors such as efficacy, safety, and patient access.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the clinical implications of these trials, and which unmet needs are being addressed or potentially fulfilled in the MCL landscape?
- In the context of the evolving treatment landscape, how do you envision the integration of emerging BTKi therapies impacting current treatment guidelines for CLL and MCL? What factors should be considered?
Advertisement
Related to this article

Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.

During OncoVenture, Careology leaders described how their platform supports patients receiving CAR T-cell therapy at home in Ohio, extends Mayo Clinic’s reach in rural Florida, and powers payer care navigation.

John Elliott, of Reimagine Care, outlined a model that pairs AI-supported triage with oncology-trained nurses, and the CEO of a large Texas practice described how the partnership has grown to include patients receiving CAR T-cell therapy.

Anemia and iron deficiency are linked to higher odds of acute heart failure during pregnancy and after childbirth, according to a study.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
2
Most Patients With Psoriasis Screened Positive for PsA at One Dermatology Clinic
3
Iron Deficiency in Heart Failure Is a Workflow Problem, Faculty Say
4
Low CRC Incidence Found After Endoscopic Mucosal Resection
5




